Dr. Richter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1468 Madison Ave.
Mount Sinai / Tisch Cancer Institute
New York, NY 10029Phone+1 212-241-7873- Is this information wrong?
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
New York Medical College at St Vincent's Hospital and Medical Center of New YorkResidency, Internal Medicine, 2005 - 2008- New York Medical CollegeClass of 2005
Certifications & Licensure
FL State Medical License 2020 - Present
NY State Medical License 2011 - 2025
NJ State Medical License 2011 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma Start of enrollment: 2013 Apr 01
- A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Start of enrollment: 2013 Apr 01
- Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab.Jeremy Orloff, Dev D Patel, Camille M Powers, Austin J Piontkowski, Robert G Phelps, Joshua Richter, Nicholas Gulati> ;JAAD Case Reports. 2024 May 1
- Like a bridge over troubled water: keeping the myeloma down en route to CAR-T.Joshua Richter> ;Blood Cancer Journal. 2024 Apr 12
- Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma...Thomaz Alexandre Costa, Kevin Pak, Aesha Patel, Nicole Felix, Bruno Almeida Costa, Tarek H Mouhieddine, Joshua Richter> ;American Journal of Hematology. 2024 Apr 12
- Join now to see all
Abstracts/Posters
- A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple MyelomaJoshua R Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate GenesJoshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide MaintenanceJoshua Richter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
How Bispecific Antibodies Could Make BCMA-Directed Therapy More AccessibleSeptember 20th, 2022- Clinical Challenges: Treatment Options in Waldenström MacroglobulinemiaDecember 17th, 2021
- Clinical Challenges: Signs, Symptoms, and Diagnosis of Waldenström MacroglobulinemiaDecember 10th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Hospital Affiliations
Mount Sinai MorningsideNew York, New York
The Mount Sinai HospitalNew York, New York
Mount Sinai Beth IsraelNew York, New York
Mount Sinai WestNew York, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
